In this podcast, we discuss 5 common errors in designing and managing IND-enabling toxicology programs with a special guest: Glenn Washer, EVP of Global Safety and Toxicology at Frontage Laboratories, Inc.

Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.

Critical reagents – the key components used in LBA – are central to ensuring the consistency and reliability of the assay and can often slow the progress of LBA due to limited availability. In this panel discussion, we examine the current scope of LBAs, the advantages and limitations including matrix interference, as well as the solutions for overcoming these. Additionally, we explore the platforms currently used and the key factors to consider when choosing a platform. Finally, we will highlight key areas for progression.